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Abstract
Because cancer registry data provide a census of cancer cases, registry data can be used to: 1) 
define and monitor cancer incidence at the local, state, and national levels; 2) investigate patterns 
of cancer treatment; and 3) evaluate the effectiveness of public health efforts to prevent cancer 
cases and improve cancer survival. The purpose of this article is to provide a broad overview of the 
history of cancer surveillance programs in the United States, and illustrate the expanding ways in 
which cancer surveillance data are being made available and contributing to cancer control 
programs. The article describes the building of the cancer registry infrastructure and the successful 
coordination of efforts among the 2 federal agencies that support cancer registry programs, the 
Centers for Disease Control and Prevention and the National Cancer Institute, and the North 
American Association of Central Cancer Registries. The major US cancer control programs also 
are described, including the National Comprehensive Cancer Control Program, the National Breast 
and Cervical Cancer Early Detection Program, and the Colorectal Cancer Control Program. This 
overview illustrates how cancer registry data can inform public health actions to reduce disparities 
in cancer outcomes and may be instructional for a variety of cancer control professionals in the 
United States and in other countries.
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INTRODUCTION
Public health surveillance, defined as the ongoing, systematic collection, analysis, 
interpretation, and dissemination of data,1 is one of the underlying pillars of all chronic 
disease programs.2 Among chronic disease programs in the United States, cancer prevention 
and control programs are unique in relying on an existing network of disease registries that 
collect and maintain high-quality surveillance data regarding incident cases. In fact, cancer 
is the only notifiable chronic condition,3 meaning that cancer data must be reported to the 
state. Cancer reporting is available for the entire US population, similar to the reporting of 
death records, because of the combined efforts of federal cancer registry programs supported 
by the Centers for Disease Control and Prevention (CDC) and the National Cancer Institute 
(NCI). The CDC and NCI have a long history of coordinating these 2 programs to build a 
national infrastructure for cancer surveillance.4,5 Since 1998, the combined data from these 
CDC and NCI cancer registry programs have been summarized in the Annual Report to the 
Nation on the Status of Cancer, a yearly update of cancer incidence and death rates and 
trends with an in-depth analysis of a selected topic, most recently featuring survival in the 
United States.6 In addition, the NCI and CDC collaborate to make nationwide data on cancer 
incidence, mortality, risk factors, screening, and other resources available for use in cancer 
control plans in the State Cancer Profiles Web site (http://statecancerprofiles.cancer.gov).
Because cancer registry data provide a census of cancer cases, registry data can be used to 
define and monitor cancer incidence at the local, state, and national levels, investigate 
patterns of cancer treatment, and evaluate the effectiveness of public health prevention 
efforts. The purpose of this article is to provide a broad overview of the history of cancer 
surveillance programs in the United States and illustrate the expanding ways in which cancer 
surveillance data are being used for cancer prevention and control. This overview may be 
informative for a variety of cancer control professionals in the United States and in other 
countries. Cancer registry data serve as the foundation for public health action to reduce 
disparities in cancer incidence, mortality, and survival.
CANCER SURVEILLANCE PROGRAMS
Surveillance, Epidemiology, and End Results Program
The NCI’s Surveillance, Epidemiology, and End Results (SEER) program is a coordinated 
system of cancer registries, strategically located across the United States, charged with 
providing timely and accurate data regarding cancer incidence, mortality, treatment, and 
survival. SEER was established in 1973 in response to the National Cancer Act of 1971, 
which mandated the collection, analysis, and dissemination of data regarding patients with 
cancer to support the prevention, diagnosis, and treatment of cancer in the United States. It 
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grew out of 2 earlier studies, the Third National Cancer Survey7 and the End Results 
Program,8 which had collected cancer survival data from 1956 to 1972 regarding patients 
diagnosed or treated at a select number of US hospitals. Over time, SEER has expanded to 
increase coverage of minority, rural, and other populations. SEER currently includes the 
states of California, Connecticut, Georgia, Hawaii, Iowa, Kentucky, Louisiana, New Jersey, 
New Mexico, and Utah, and the metropolitan areas of Detroit and Seattle-Puget Sound (Fig. 
1). All SEER registries are funded by the NCI and their respective states, and the registries 
in Kentucky, Greater California, New Jersey, Louisiana, and Greater Georgia also are funded 
by CDC’s National Program of Cancer Registries. SEER also collects data regarding 
American Indians/Alaska Natives in Arizona and Alaska, and of the Cherokee Nation. 
Currently, SEER covers approximately 30% of the US population, and records 400,000 new 
cancer cases diagnosed annually.
SEER routinely collects data regarding patient demographics, primary tumor site, tumor 
morphology and stage at diagnosis, initial course of cancer treatment, and follow-up for vital 
status information. Patient follow-up data are obtained by linking with administrative 
databases, mainly the National Death Index, Social Security Administration, state vital 
records departments, and the Centers for Medicare and Medicaid Services. In addition to 
date and cause of death for deceased patients, registries collect a date of last contact within 
22 months of the date of their annual data submission to SEER for a minimum of 90% of all 
registered patients with cancer, both living and deceased (http://seer.cancer.gov/tools/
SEER_2015.instructions.pdf). Date of last contact for living patients allows for the 
identification of patients who are likely lost to follow-up due to immigration or for other 
reasons. In SEER survival calculations, survival is calculated from the date of diagnosis to 
the date of last contact for patients not known to have died. In other words, SEER does not 
assume patients are alive between the date of last contact and the end of study date.
SEER also plays an important role in supporting scientific and clinical research on cancer. 
As a research resource, SEER data are made available to researchers and the public through 
dissemination of reports, databases, analytical software, and linkages to other data sources 
(http://seer.cancer.gov/seerstat). SEER data also are linked to national databases to 
complement the registry data with other information such as risk factors, detailed treatment 
information from claims, and quality of life (https://seer.cancer.gov/resources/
linked_databases). The SEER-Medicare data (http://healthcaredelivery.cancer.gov/
seermedicare) have been used extensively on studies assessing the patterns of care for 
patients with cancer and the cost of cancer treatment.9,10
National Program of Cancer Registries
The National Program of Cancer Registries (NPCR) is the CDC’s largest disease 
surveillance system in the United States. The purpose of this program is to provide 
population-based cancer incidence data on which to base national, state, and local health 
planning. The NPCR was established in 1992 by the US Congress through Public Law (P.L.) 
102–515, the Cancer Registries Amendment Act. This law authorizes the CDC to: provide 
funds and technical assistance to states and territories to improve existing cancer registries; 
plan and implement registries where they did not exist; help develop model legislation and 
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regulation for states to enhance the viability of registry operations; set standards for data 
completeness, timeliness, and quality; provide training for registry personnel; and help 
establish a computerized reporting and data processing system.
P.L. 102–515 provides the framework for the legal support needed to operate central cancer 
registries by requiring that funded states develop legislation authorizing the establishment of 
a central cancer registry and provide regulations as specified in the law. These regulations 
provide the legal basis for the following: 1) case reporting from all facilities and 
practitioners; 2) access to medical records; 3) reporting of uniform data; 4) protection of 
patient confidentiality; 5) access to data by researchers; 6) authorization to conduct research; 
and 7) protection from liability for individuals who abide by the law.
In 1994, the NPCR began providing financial support and technical assistance to state health 
departments for the operation of statewide, population-based cancer registries. State health 
departments or their authorized designees were eligible for 1 of 2 funding categories. The 
first category of funding supported the enhancement of existing cancer registries, and the 
second supported the planning and implementation of a new cancer registry where none had 
previously existed. After the first program announcement in 1994, 42 states and the District 
of Columbia (34 enhancement programs and 9 planning programs) were awarded funds. 
After the second program announcement in 1997, 3 additional states and 3 territories (2 
enhancement programs and 4 planning programs) were awarded funds. Currently, the NPCR 
funds support 45 states, the District of Columbia, Puerto Rico, and the Jurisdictions of the 
Pacific Islands (Fig. 1), and all funded programs are required to match federal funds. The 
NPCR covers approximately 96% of the US population and records more than 1.6 million 
new cancer cases diagnosed annually.
NPCR-funded central cancer registries are required to collect and report information on all 
state residents who are diagnosed with or treated for cancer, including residents who are 
diagnosed and treated outside of their state of residence. P.L. 102–515 defined reportable 
cancer as “each form of in situ and invasive cancer (with the exception of basal cell and 
squamous cell carcinoma of the skin).” Benign brain and central nervous system tumors also 
must be collected and reported to the CDC. Data required to be collected are similar to 
SEER and include: cancer incidence; demographic information; administrative information, 
including the date of diagnosis and the source of information; and pathological data, 
including cancer site, stage at diagnosis, and type of treatment. To reduce racial 
misclassification of American Indian and Alaska Native populations, central cancer 
registries have worked with the CDC and the Indian Health Service (IHS) to link registry 
records with IHS patient registration records.11
NPCR registries record vital status information and the date of last contact as available, but 
the registries are not funded or required to meet follow-up standards. The NPCR arranged 
for linkage with the National Death Index to be available at no additional cost to its 
registries, to encourage the registries to comprehensively ascertain deaths within the United 
States. These linkages do not provide follow-up information regarding living patients or 
patients who moved out of the country between the time of their diagnosis and death. 
Despite differences in follow-up procedures, SEER and NPCR survival estimates have been 
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shown to be comparable,12 and are routinely made available free of charge from the North 
American Association of Central Cancer Registries (NAACCR) Web site.13
An economic evaluation of central cancer registry operations by the CDC found that costs 
varied across registries and identified opportunities for improved efficiency and reduced 
costs.14–16 Similar methods have been applied to examine costs for cancer registration in 
low-income and middle-income countries.17
The U.S. Cancer Statistics Incidence and Mortality Web-Based Report (www.cdc.gov/uscs) 
contains the official federal statistics on high-quality cancer incidence data from the NPCR 
and SEER registries and mortality data from the CDC’s National Vital Statistics System.18 
In 2017, the CDC launched United States Cancer Statistics: Data Visualizations, an 
interactive, online tool that displays the latest official federal cancer data by cancer type, 
state, demographics, and year (https://nccd.cdc.gov/USCSDataViz). Cancer incidence data 
are provided to the CDC’s National Environmental Public Health Tracking Network (http://
ephtracking.cdc.gov/showCancer-Main.action). In addition, the combined data from NPCR 
and SEER analytic data sets are available to researchers (www.cdc.gov/cancer/public-use), 
and comparative effectiveness research data19 also are available to researchers.
North American Association of Central Cancer Registries
Both federally funded registry programs (SEER and NPCR) work closely with the 
NAACCR to promote cancer incidence surveillance in the United States and Canada. 
Established in 1987, NAACCR Inc. is a collaborative umbrella organization for cancer 
registries, governmental agencies, professional associations, and private groups in North 
America interested in enhancing the quality and use of cancer registry data. All central 
cancer registries in the United States and Canada are members. The NAACCR develops and 
promotes uniform data standards for cancer registration; provides education and training; 
certifies population-based cancer registries; aggregates and publishes data from central 
cancer registries6; and promotes the use of cancer surveillance data and systems for cancer 
control and epidemiologic research, public health programs, and patient care to reduce the 
burden of cancer.
The NAACCR works with all member cancer surveillance entities to assure comparability of 
data across jurisdictions by developing consensus standards. To our knowledge, these 
standards are the most comprehensive of any disease surveillance system, and have been in 
effect for more than 25 years, contributing to the foundation of consistent and reliable cancer 
surveillance data. The standards pertain to case definitions, coding systems in use by 
registries, coding rules, standardized edits, data transmission formats, and best practices for 
the operation of population-based cancer registries. NAACCR standards are updated 
annually (http://www.naaccr.org/StandardsandRegistryOperations/VolumeII.aspx).
In 1992, NAACCR began independent annual reviews of member registries’ data for 
compliance of completeness, accuracy, and timeliness with NAACCR standards. In 1997, 
this process was formalized into a certification program, whereby NAACCR evaluates the 
data using standard, objective measures. Registries that meet the highest standards for data 
quality are recognized through NAACCR certification. Over time, the NAACCR 
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certification standards have provided independent and objective measures of the improved 
quality of cancer surveillance data in the United States and Canada. In 2017, 55 population-
based cancer registries in the United States, covering 94% of the US population, met 
NAACCR certification levels (http://www.naaccr.org/certified-registries/).
CANCER CONTROL PROGRAMS
National Comprehensive Cancer Control Program
Partnerships (or coalitions) with public and private sector organizations are essential for 
effective public health program implementation.20 The CDC’s National Comprehensive 
Cancer Control Program (NCCCP) was established in 1998 to support a coalition-based 
approach to cancer prevention and control. The NCCCP brings cancer control programs, 
community stakeholders, and state and local organizations together to strategically plan and 
implement cancer control activities. State registry data are the foundation of a state’s 
comprehensive cancer control plan. Cancer coalitions work to reduce the burden of cancer in 
their communities by addressing a wide breadth of cancer prevention and control issues 
across multiple cancer types and levels of intervention. This highly organized public health 
approach provides a powerful constituency of professional, political, advocacy-oriented, and 
lay members to set the agenda for and advance cancer prevention and control efforts. The 
NCCCP supports cancer control coalitions in all 50 states, the District of Columbia, 7 US-
affiliated Pacific Islands and territories, and among 7 tribes and tribal organizations (http://
www.cdc.gov/cancer/ncccp/index.htm).
The CDC first awarded NCCCP funding to 6 grantees in 1998. Since then, the number of 
programs receiving NCCCP funding has grown to 65. Grantees convene stakeholder 
meetings, assess epidemiologic data, and prepare and implement formal plans to reduce the 
incidence and burden of cancer in their state and local areas. The NCCCP currently focuses 
on 6 priorities: 1) emphasizing primary prevention; 2) coordinating early detection and 
treatment activities; 3) addressing public health needs of cancer survivors; 4) implementing 
systems and environmental changes to sustain cancer control; 5) eliminating health 
disparities to achieve health equity; and 6) using evidence to evaluate impact. Additional 
information regarding activities around these 6 priorities can be found on the NCCCP Web 
site (https://www.cdc.gov/cancer/ncccp/). The following information describes those 
NCCCP activities that are most strongly related to improving cancer survival.
Recommended strategies for cancer survivors were identified in the 2004 National Action 
Plan for Cancer Survivorship: Advancing Public Health Strategies (NAPCS), which 
provided nationally accepted, evidence-based interventions for individuals diagnosed with 
cancer (cancer survivors) and their family members, friends, and caregivers.21 The NAPCS 
recommends strategies focused on 4 core public health areas: 1) surveillance and applied 
research; 2) communication, education, and training; 3) programs, policies, and 
infrastructure; and 4) access to quality care and services. The majority (94%) of cancer 
coalitions supported by the NCCCP currently are working within their communities to 
pursue these public health strategies in support of cancer survivors.22 A recent assessment of 
the implementation of NAPCS revealed that 64% of NCCCP grantees include NAPCS 
strategies in their own program action plans.22 For example, grantees in New Mexico, South 
White et al. Page 6
Cancer. Author manuscript; available in PMC 2018 March 12.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Carolina, Vermont, and Washington state and from the Fond Du Lac tribe have each 
implemented activities in all 4 of the NAPCS’s strategy areas.23
Survivorship care plans were identified by the Institute of Medicine for patients and their 
providers.24 As people can live long after a cancer diagnosis, providing a summary of each 
cancer patient’s treatment is an essential part of developing a complete survivorship care 
plan. The CDC has developed a secure, Web-based application that allows providers to 
import previously collected cancer registry data to facilitate the development of individual 
survivorship care plans (http://www.cdc.gov/cancer/npcr/tools/registryplus/
wp_survmodule.htm). Providers have access to the information available in the cancer 
registry, and can edit or add to a patient’s diagnosis and treatment information. Starting with 
one registry,25 this pilot project has expanded and is being adopted by other cancer registries 
through the NCCCP.
In 2015, the CDC funded a supplemental award to NCCCP grantees in Indiana, Kansas, 
Louisiana, Michigan, South Dakota, and Washington to implement a broad set of evidence-
based survivorship strategies. Strategies focus on increasing core surveillance and 
communications between community-based and clinical health care organizations and 
include using data systems to increase the use of survivorship care plans, increasing patient 
navigation programs to assist cancer survivors, and using electronic learning series to 
increase the education of providers concerning survivor care. Together, these strategies help 
to specifically identify and characterize the survivor population and address survivor needs 
from diagnosis through treatment and after treatment. These grantees are partnering with 
their state cancer registries and hospital registries to link data regarding incidence and cancer 
stage to patient electronic health record data to improve care planning in specific health 
systems. NCCCP grantees are uniquely positioned to help cancer control programs plan and 
implement policy, systems, or environmental changes that will have an impact on the quality 
of life of cancer survivors.
National Breast and Cervical Cancer Early Detection Program
Through Congressional legislation passed in 1990, the CDC established the National Breast 
and Cervical Cancer Early Detection Program (NBCCEDP)26–28 to provide access to quality 
cancer screening for low-income women who meet program eligibility criteria (income, 
insurance status, and national screening guidelines).29 Since then, the NBCCEDP has 
become the only nationwide, organized cancer early detection program in the United States,
30
 cumulatively screening nearly 4.9 million women. In 2017, the program awarded funding 
to 50 states, the District of Columbia, 13 tribes and tribal organizations, and 6 US territories 
to maintain screening programs within their jurisdictions.
From the beginning, demographic and clinical data called Minimum Data Elements have 
been collected on every woman screened by the NBCCEDP.31 These data are used by the 
CDC and individual grantees to monitor the number of women screened and their screening 
outcomes (abnormal screening results and diagnostic tests), as well as to assess performance 
in achieving program quality standards32 and to conduct program studies.33 The CDC 
requires grantees to link Minimum Data Elements data to their state cancer registries data 
and in doing so, they have created an information infrastructure with the capacity to provide 
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standardized data regarding the diagnosis and cancer stage for women identified by the 
program as having cancer. In addition, the linked data set benefits cancer registries by 
identifying potentially missed cancer cases and providing missing race data. For example, 
studies have been performed using the data set to compare stage of disease at the time of 
diagnosis with screening histories among women with cancer.34–36
Colorectal Cancer Control Program
Beginning in 2009, the CDC awarded funds to 29 state and tribal grantees to implement the 
Colorectal Cancer Control Program (CRCCP).37,38 A second round of funding was awarded 
to 30 grantees (states, universities, and 1 tribe) in 2015, stipulating a decided shift in 
program emphasis to increase and integrate the use of recommended evidence-based 
interventions from the Community Preventive Services Task Force (www.the-
communityguide.org/findings/cancer-screening-multi-component-interventions-colorectal-
cancer) to increase colorectal cancer screening within partner health systems, such as 
federally qualified health centers. CRCCP priority interventions include client and provider 
reminder systems, provider assessment and feedback, and removal of structural barriers to 
screening. Among the initial CRCCP programs, there was a higher use of evidence-based 
interventions compared with nongrantees39; however, fewer of these were implemented by 
CRCCP grantees than other interventions, although they potentially have a greater impact on 
screening rates.40
Enhancing Cancer Genomic Best Practices
The CDC currently supports 5 state health departments (Colorado, Connecticut, Michigan, 
Oregon, and Utah) in developing or expanding programs that rely on education, surveillance, 
and policy to assist individuals who are at high risk of developing cancer based on inherited 
genetic factors that predispose some persons to developing certain cancers (http://
www.cdc.gov/cancer/breast/what_cdc_is_doing/genomics_foa.htm). The current program 
began in 2014, and follows a previous 3-year program with 3 grantees and earlier genomic 
activities supported by the CDC. Under this program, state grantees are encouraged to take 
advantage of collaborations with state cancer registries and comprehensive cancer control 
programs. The objectives of this program are to assess the burden of cancers based on 
inherited genetic factors and the use of services for genetic counseling and testing, increase 
knowledge about such services among health care providers and the general public, and 
improve access to these services for persons at high risk.
DISCUSSION
In the United States, cancer claims nearly 600,000 lives each year.41 It is the leading cause 
of premature death,42 and the leading cause of death in midlife (aged 45–64 years).43 In 
addition, well over 1.5 million individuals each year are told they have cancer.41 The nation 
is facing the added challenge of responding to the aging of the population and the projected 
increases in the numbers of people diagnosed, living with, and dying of cancer.44–46 It is 
widely accepted that much of this cancer burden could be reduced through the expanded 
implementation of proven prevention interventions and programs by public health agencies.
47,48
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Cancer control planning and evaluation at the population level is a data-driven process. All 
major cancer control programs rely on state cancer registry data to inform planning efforts, 
allocate resources to specific areas or populations, or evaluate progress. Cancer registries 
have been used to provide compelling data documenting variations in cancer incidence and 
cancer mortality within and among different populations.49–52 Combined data from the 
NPCR and SEER registries have provided sufficient numbers of incident cases to examine 
rare cancers, specific histologic types, cancers at specific ages, and regional variations.53–58 
In addition to contributing critical knowledge regarding patterns in cancer occurrence and a 
resource for cancer researchers, cancer surveillance data provide essential data with which to 
guide cancer prevention and control activities at the national, state, and local levels. To have 
the greatest impact on promoting health and improving survival after a cancer diagnosis, 
partnerships between public health agencies, health care providers, and across multiple other 
sectors will be essential to address the underlying social determinants of persistent health 
disparities.59
The combination of problems and challenges are unique to each state, and local data are 
critical to inform local activities. Measures of cancer survival at the population level rely on 
our extensive surveillance infrastructure, particularly a national network of high-quality 
cancer registries. These cancer survival measures offer new insights into the need to address 
inequities in cancer diagnosis, treatment, and survivorship.60 Together with data regarding 
cancer incidence and death rates, cancer survival measures provide a comprehensive picture 
of the burden of cancer in a population and support public health efforts to prevent new 
cancers, extend survival and quality of life after a cancer diagnosis, and reduce cancer health 
disparities.
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Figure 1. 
Funding status for cancer registries supported through the Centers for Disease Control and 
Prevention’s National Program of Cancer Registries or the National Cancer Institute’s 
Surveillance, Epidemiology, and End Results Program. Source: Division of Cancer 
Prevention and Control, Centers for Disease Control and Prevention (http://www.cdc.gov/
cancer/npcr/index.htm).
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